Molecular Partners AG.
MOLN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Molecular Partners AG is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of a new class of custom-built protein therapeutics known as DARPins. These DARPins are designed to address significant unmet medical needs in various therapeutic areas, i...Show More
Better Health for All
10
Molecular Partners' core business is developing DARPin therapeutics to transform the lives of people with serious diseases, primarily focusing on oncology (small cell lung cancer, acute myeloid leukemia, cholangiocarcinoma, ovarian cancer) and infectious diseases.
1
Their COVID-19 antiviral candidate, Ensovibep, demonstrated an 80% reduction in the combined risk of hospitalization, emergency room visits, or death in a Phase 2 study.
2
The company's DARPin platform is designed to be a rapid and cost-effective drug discovery engine, and all DARPins are produced through a rapid, high-yield microbial fermentation process.
3
The company has an MP0712 compassionate care program in South Africa and targets diseases prevalent in over 80% of patients with ovarian cancer and over 85% of patients with small cell lung cancer.
4
The MP0533 Phase 1/2a clinical trial showed an acceptable safety profile after dose adjustment.
5
The company's Annual Report on Form 20-F for the year ended December 31, 2024, is to be filed with the U.S. Securities and Exchange Commission (SEC).
6
Molecular Partners invested CHF 48.6 million in R&D in 2024 and raised approximately $20 million in October 2024 to finance the development and expansion of its radiopharmaceutical pipeline.
7
During the COVID-19 pandemic, Molecular Partners developed Ensovibep, an antiviral therapeutic candidate, which showed high inhibitory potency against all COVID-19 variants of concern, including Omicron, as of December 2021.
8
The company conducts clinical trials, including Phase 1/2a studies for MP0533 (NCT05673057) and MP0712, and a Phase 2 investigator-initiated trial for MP0317 (NCT07036380).
9
As of December 31, 2024, 84% of the company's 158.5 full-time equivalent employees were in R&D-related functions.
10
The company's MP0621 program is designed to induce killing of hematopoietic stem cells as a next-generation conditioning regimen for HSC transplantation.
11
Fair Money & Economic Opportunity
0
Molecular Partners AG is a biopharmaceutical company focused on developing protein therapeutics.
1
Its core business does not involve lending, insuring, moving, or storing money for consumers.
2
Therefore, the company does not offer financial products or services that would be assessed by the KPIs under the 'Fair Money & Economic Opportunity' value.
3
All KPIs related to financial products, fees, lending, debt, and financial literacy are scored as 'Not applicable' (0) as there is no evidence of such activities within the scope of this value.
4
Fair Pay & Worker Respect
0
Molecular Partners announced a reduction of its workforce by no more than 40 positions, representing approximately 24% of its total workforce, in June 2025.
1
A consultation process with affected employees is underway, and support including severance packages and career transition assistance will be offered.
2
The company's CEO received a total compensation of CHF 1.10 million in 2022.
3
Fair Trade & Ethical Sourcing
0
No specific data points or evidence regarding fair trade certifications, supplier audits, forced/child labor incidents, supply chain traceability, remediation speed, ethical clauses in contracts, high-risk materials, or supplier diversity spend were found in the provided article.
1
Honest & Fair Business
-60
Molecular Partners has a formal whistleblower policy that prohibits retaliation and provides a secure helpline (phone, email, web-based tool) for reporting violations.
1
However, there is no evidence of independent investigation processes. The company is facing a class action lawsuit (Freudiger v. Molecular Partners AG, No. 22-cv-05925 (S.D.N.Y.)) alleging securities violations related to false or misleading statements about drug development and FDA approval likelihood, which indicates a below-average ESG controversy score.
2
A formal anti-corruption policy exists, stating the company does not offer bribes or kickbacks and interacts legitimately with healthcare professionals and government entities.
3
However, the policy lacks clear guidance on facilitation payments and gift thresholds, and there is no evidence of training frequency or effectiveness metrics.
Kind to Animals
0
No evidence available to assess Molecular Partners AG on Kind to Animals.
No War, No Weapons
0
No relevant information was found in the provided articles to assess the company against the 'No War, No Weapons' ethical value. The single article provided explicitly states its content is unavailable.
1
Planet-Friendly Business
0
No specific, quantitative data points for any of the Planet-Friendly Business KPIs were found across the provided articles. The articles explicitly state a lack of publicly available ESG metrics, carbon emissions data, reduction targets, or other relevant environmental performance indicators for Molecular Partners AG.
1
Respect for Cultures & Communities
0
The provided articles, which are primarily financial reports and corporate highlights, do not contain specific, concrete data points relevant to the ethical value of 'Respect for Cultures & Communities'. While one article mentions the establishment of an ESG working group and a plan to create a baseline status evaluation for an ESG plan, this is a general initiative and does not provide specific evidence for the existence and implementation of a formal cultural impact assessment protocol.
1
Information listed as 'local_employment_ratio' in some articles refers to the percentage of employees in R&D-related functions, not the proportion of the workforce recruited from local communities, and therefore does not apply to the KPI definition.
2
Safe & Smart Tech
0
No specific, concrete evidence was found in the provided articles to assess Molecular Partners AG (MOLN.US) against any of the 'Safe & Smart Tech' KPIs. Articles discussing a data breach and security deficiencies explicitly refer to a managed services provider named Ntirety and a medical diagnostic testing laboratory (MTL).
1
While one article's summary title includes 'MOLN.US (Ntirety)', the body of the article clearly details the breach as occurring on Ntirety's network and MTL suing Ntirety, with no explicit statement linking Molecular Partners AG directly to this incident or identifying it as Ntirety.
2
Other articles from Molecular Partners AG's own websites provide general statements of commitment to ethical standards and outline privacy policies, but lack specific, measurable data or actions related to cybersecurity investment, data breaches, AI ethics, or other technical security and privacy practices that could be mapped to the rubric's quantitative thresholds.
3
Zero Waste & Sustainable Products
-20
Molecular Partners utilizes 212Pb in its Radio-DARPin Therapeutic, which has a relatively short half-life of 10.6 hours.
1
This characteristic inherently leads to easier waste management for the radioactive material, contributing to the minimization of the hazardous waste burden.
2
No other specific, quantifiable evidence was found regarding MOLN.US's performance in waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.